SCHEMBL4979296

SCHEMBL4979296

CC(C)CN1C(=O)NC2(C(=O)Nc3ccc(F)cc32)C1=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 4/20 0.41
CASP6 P55212 1/20 0.40
CYP1A2 P05177 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
AKR1A1 P14550 1/20 0.39
CNR1 P21554 2/20 0.38
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SNRNP200 O75643 2/20 0.36
TRPA1 O75762 1/20 0.36
RAB9A P51151 1/20 0.35
HTR7 P34969 2/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
GFER P55789 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3950566 0.80 AKR1B1 (0.42) AKR1B1CYP1A2MAPTCYP2C19KMT2A
SCHEMBL4254358 0.79 AKR1B1 (0.50) AKR1B1AKR1A1TRPA1
SCHEMBL3952571 0.76 OPRL1 (0.43) AKR1B1CYP1A2MAPTCYP2C19KMT2A
SCHEMBL3957230 0.75 ALDH1A1 (0.39) AKR1B1CYP1A2MAPTCYP2C19KMT2A
SCHEMBL4979970 0.74 AKR1B1 (0.41) AKR1B1CYP1A2CYP2C19KMT2ACNR1
SCHEMBL4979166 0.74 CYP1A2 (0.39) AKR1B1CYP1A2MAPTCYP2C19KMT2A
SCHEMBL4979292 0.73 CYP1A2 (0.43) AKR1B1CYP1A2MAPTCYP2C19KMT2A
SCHEMBL4976847 0.72 TRAP1 (0.39) AKR1B1CYP1A2MAPTCYP2C19KMT2A
SCHEMBL4259941 0.70 AKR1B1 (0.48) AKR1B1AKR1A1
SCHEMBL4983724 0.69 ALDH1A1 (0.41) AKR1B1CASP6CNR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984374-A1 USE OF SPIRO Ý IMIDAZOLIDINE-4, 3'-INDOLE¨2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 AstraZeneca AB (SE) 2008-10-29 EP disclosed
WO-2007091946-A1 USE OF SPIRO [ IMIDAZOLIDINE-4, 3'-INDOLE] 2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 ASTRAZENECA AB (SE) 2007-08-16 WO disclosed